Hyderabad, India, July 19, 2016 --(PR.com
)-- Industry Experts unveiled the new market research report on Influenza. The new global report ‘Global Influenza Market – Vaccines and Therapeutics’ reveals that the market for seasonal influenza vaccines is estimated at 543 million doses valued at US$4.9 billion in 2016 and projected to touch US$714 million doses equated to US$7.9 billion by 2022. In terms of market value, North America is estimated the largest market with US$2.1 billion in 2016 while Europe is projected to be the fastest growing market for Influenza vaccines during the analysis period 2016-2022 with a CAGR of 11.7%.
The influenza virus has been implicated in infecting millions of individuals on an annual basis, with vaccination programs against seasonal influenza infections necessitating the manufacture of hundreds of million doses within a very short time period. The emergence of innovative production systems based on mammalian or insect cell cultures have resulted in surmount the hurdles associated with the egg-based production system. These industrially well-established production systems provide a faster and more flexible response to pandemic threats.
The existing range of influenza vaccines are produced in fertilized eggs, the embryo of which is infected in order that the virus can proliferate. Following a period of incubation, the virus is harvested and purified. This system of production is complicated and lacking in the event of a pandemic due to the possibility of generating low yields, not being amenable to rapid scale-up and being dependent on the availability of eggs. Global authorities have acknowledged problems associated with manufacturing vaccines based on eggs, resulting in creating a need for developing alternative vaccine production systems. The current scenario has been focusing on the development of manufacturing systems based on plants, bacteria, yeast and cell cultures.
Worldwide market for Influenza Vaccines is analyzed in both volumes in doses and value in USD for the period from 2012 through to 2022. The market for influenza therapeutics is analyzed in terms of value only at a global level. The global market for overall influenza is estimated to be US$6.1 billion in 2016 and anticipated to reach US$10.2 billion by 2022, witnessing a robust 8.5% CAGR between 2016 and 2022. Vaccines account for about 80% of the influenza market while therapeutics account for the remaining. However, therapeutics segment is projected to be the fastest growing with a CAGR of 11% during the aforementioned analysis period.
The report reviews, analyses and projects the Influenza therapeutics market at the global level while vaccines market is explored in and the regional markets including North America, Europe, Asia-Pacific, South & Central America and Middle East & Africa.
This 128 page market research report includes 30 charts (includes a data table and graphical representation for each chart), supported with meaningful and easy to understand graphical presentation, of market numbers. This report profiles 16 key global players and 39 major players across North America – 8; Europe – 10; Asia-Pacific – 20 and South & Central America – 1. The research also provides the listing of the companies engaged in research and development, manufacturing and supply of influenza vaccines and therapeutic. The global list of companies covers addresses, contact numbers and the website addresses of 80 companies.
Hyderabad, India based Industry Experts is a multi industry focused business information provider.
For more details, please visit http://industry-experts.com/verticals/healthcare-and-pharma/global-influenza-market-vaccines-and-therapeutics